Neurizon Therapeutics Limited (ASX:NUZ) has applied for the quotation of 461,538 ordinary fully paid shares issued to an investor relations advisor as part consideration for services provided, at a deemed issue price of $0.065 per share, according to an Appendix 2A filing dated 9 November 2026.

Key Points

  • 461,538 ordinary fully paid NUZ shares issued on 9 November 2026 at a deemed price of $0.065 (6.5 cents) per share
  • Shares issued to an investor relations advisor as part consideration for services provided, not for cash
  • The issue was previously notified to ASX via an Appendix 3B dated 30 June 2026
  • No further securities issues are yet to take place to complete the transaction referenced in the Appendix 3B
  • Total quoted ordinary fully paid shares on issue following quotation: 853,878,607

Share Issue Terms and Consideration

The 461,538 ordinary fully paid shares were issued on 9 November 2026 at a deemed issue price of $0.065 per share. According to the filing, the consideration provided for the securities was non-cash, with the shares issued to an investor relations advisor as part consideration for services provided. The filing confirms the securities are being quoted pursuant to a placement or other type of issue, as categorised under the previously lodged Appendix 3B. No cash consideration was received by the company in connection with this issuance.

Previously Disclosed Transaction Details

The share issue referenced in this quotation application was previously announced to the market through an Appendix 3B lodged on 30 June 2026, titled "New - Proposed issue of securities - NUZ." The company confirmed in the current filing that there are no further issues of securities yet to take place to complete the transaction referred to in that Appendix 3B. The quotation application was submitted as a new announcement on 9 November 2026 by Neurizon Therapeutics Limited, registered under ABN 35 094 006 023.

Issued Capital Following Quotation

Following the quotation of the 461,538 shares, Neurizon Therapeutics' total quoted ordinary fully paid securities on issue stand at 853,878,607. The company also has a range of unquoted securities on issue, including options expiring 5 February 2028 exercisable at $0.26 (384,000), options expiring 30 June 2032 at $0.20 (9,539,210), options expiring 31 August 2033 at $0.16 (2,044,025), options expiring 31 August 2034 at $0.0594 (5,947,668), and 16,245,860 performance rights.